title: Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).
abstract: Circulating HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor were measured in 13 zidovudine-intolerant patients (8 with ARC and 5 with AIDS) treated with dideoxyinosine (ddI). Measurements were made at baseline and at several intervals during therapy. Mean levels of HIV P24 antigen decreased early and significantly (P less than 0.01) after 2 weeks of ddI administration and remained low at weeks 8 and 12. In addition, mean SCD8 levels decreased late and significantly (P less than 0.02) after 16 weeks of ddI treatment and remained low at 24 weeks. In contrast, ddI administration had no substantial effect on mean levels of beta 2-microglobulin, neopterin, soluble CD4, and soluble interleukin-2 receptor. ddI administration appears to have been associated with early reduction of HIV P24 antigen levels and later reduction of SCD8 mean levels in these patients.
authors.affiliation: AIDS Clinical Trials Unit, St. Luke's-Roosevelt Hospital Center, New York, NY 10019.
authors.forename: M M
authors.initials: MM
authors.lastname: Reddy
authors.forename: G F
authors.initials: GF
authors.lastname: McKinley
authors.forename: M H
authors.initials: MH
authors.lastname: Grieco
mesh_terms: D000386:AIDS-Related Complex / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D015704:CD4 Antigens / Q000097:blood; D016827:CD8 Antigens / Q000097:blood; D016049:Didanosine / Q000627:therapeutic use*; D004361:Drug Tolerance; D016655:HIV Core Protein p24 / Q000097:blood; D006801:Humans; D019798:Neopterin; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D012995:Solubility; D015215:Zidovudine / Q000009:adverse effects; D001613:beta 2-Microglobulin / Q000378:metabolism
chemical_list: D015704:CD4 Antigens; D016827:CD8 Antigens; D016655:HIV Core Protein p24; D015375:Receptors, Interleukin-2; D001613:beta 2-Microglobulin; D001708:Biopterins; D015215:Zidovudine; D019798:Neopterin; D016049:Didanosine